Zhichen Sun

Hepatitis B virus (HBV) induces the expression of interleukin-8 that in turn reduces HBV sensitivity to interferon-alpha

Platelet factor 4–induced T _H 1-T _reg polarization suppresses antitumor immunity

A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies

Nanomaterials for T-cell cancer immunotherapy

Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells

Targeting innate sensing in the tumor microenvironment to improve immunotherapy

Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer

mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth

Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells

PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment

Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA

Opportunities for Treg cell therapy for the treatment of human disease

IFN-λ inhibits HIV-1 integration and post-transcriptional events in vitro, but there is only limited in vivo repression of viral production

HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection

Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy

Polymorphisms in melanoma differentiation‐associated gene 5 link protein function to clearance of hepatitis C virus

Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity

Synthetic cytokine circuits that drive T cells into immune-excluded tumors

CTLA-4 Limits Anti-CD20–Mediated Tumor Regression

Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity

A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer

Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance

Hepatitis B Virus Induces a Novel Inflammation Network Involving Three Inflammatory Factors, IL-29, IL-8, and Cyclooxygenase-2